PIRS, shares trade on Friday in the OTC market

By Julia Schmitt, Sector & Peer Group desk. Reviewed prior to publication on 2026-06-26, 19:40.

Pieris Pharmaceuticals (US72016P1057) is tied to U.S. trading on Friday, with its listing context centered on the OTC market. The company sits in biotechnology, and that venue anchor fits the international trading backdrop for U.S.-listed small-cap names.

Friday sector read

The available market context for Friday points to a broader equities session that recovered from earlier weakness. Barchart noted that U.S. stock indexes recovered from their worst levels after the University of Michigan's US June consumer sentiment index was revised upward, while strength in software stocks supported the market.Barchart market overview

Peer group lens

For biotech investors, the comparison set usually includes other U.S. small-cap drug developers and platform names that trade with limited liquidity and sharp sentiment swings. That peer-group lens matters more than broad index membership for a name such as Pieris Pharmaceuticals.

What the company sells

Pieris has focused on antibody-based therapeutics and partnerable drug discovery programs, with its business built around clinical development and collaboration economics. The company has historically worked on platform science rather than a mass-market product lineup.

Where the stock trades today

Pieris Pharmaceuticals shares traded at unavailable as of 2026-06-26 19:40 UTC.

This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.